EyePoint Pharmaceuticals, Inc. – FDA 483, Aug 28, 2019
EyePoint Pharmaceuticals, Inc. in Watertown, MA, was cited for significant deficiencies across its manufacturing operations, particularly concerning quality control, investigations, and aseptic processing. The inspection revealed failures in investigating product complaints, out-of-specification results, and environmental monitoring excursions, alongside issues with data integrity in computer systems and inadequate maintenance of cleanroom conditions. The firm also demonstrated poor control over stability studies, equipment calibration, cleaning procedures, and supplier qualification for critical components.
ID · 8682ee17-ffa8-4d02-b73e-0088759e15d8
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.